Compound Herbal Formula (TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy
The Effects of Compound Herbal Formula(TPE-1) for Leukopenia and Cancer-related Fatigue in Breast Cancer Patients With Radiotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 886
- Shuang Ho Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- breast cancer
- age between 18 to 70 yrs
- finished chemotherapy (adriamycin ), will receiving radiotherapy
- Chinese population
- KP$ between 40-100
- ECOG < 2
- WBC >4X10(9)/L and Hb > 10g/dl
- Assigned informed concent.
Exclusion Criteria:
- receiving operation during 14 days
- blood transfusion during one month.
- ALT >100mg/dL
- Creatinine >2.0mg/dL
- Total bilirubin >2.0mg/dL
- Infection
- prolation
- Taking anti-seizure , psychological drugs or any drugs not suitable patients
- AIDS or any disease diagnosed by physician and not suitable patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: herbal A
dilute of (TPE-1) decoction.
|
100 ml /Qd for 6 weeks(42 days)
Other Names:
|
|
Experimental: herbal B
TPE-1 decoction (100 ml)
|
100 ml /Qd for 6 weeks(42 days)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the % change of white blood cell(WBC) count
Time Frame: 6 weeks
|
WBC will be checked before taking TPE ans after taking TPE-1.
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hemoglobin (Hb)
Time Frame: 6 weeks
|
The Hb will be checked before and after kaking TPE-1
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TPE-1-breast Ca
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.